Drug intelligence / Profile preview

paroxetine + fluconazole

Development stage: Unknown
Lead developer: GSK
Modality: Small Molecules
Administration: Oral

Overview

A combination of paroxetine, a selective serotonin reuptake inhibitor (SSRI), and fluconazole, an antifungal medication. This combination has been investigated for its potential neuroprotective effects in HIV-associated neurocognitive disorder (HAND). Both drugs have shown neuroprotective effects in in-vitro models of HIV protein mediated neuronal injury.

Targets

SERT (Sodium-dependent serotonin transporter)

Beyond the preview

Go deeper on paroxetine + fluconazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on paroxetine + fluconazole.

Explore the full profile